AR014949A1 - Derivados de tiazol, procedimiento para su preparacion, composicion farmaceutica que los contiene, compuestos intermediarios y su uso para la manufacturade un medicamento - Google Patents
Derivados de tiazol, procedimiento para su preparacion, composicion farmaceutica que los contiene, compuestos intermediarios y su uso para la manufacturade un medicamentoInfo
- Publication number
- AR014949A1 AR014949A1 ARP980106723A ARP980106723A AR014949A1 AR 014949 A1 AR014949 A1 AR 014949A1 AR P980106723 A ARP980106723 A AR P980106723A AR P980106723 A ARP980106723 A AR P980106723A AR 014949 A1 AR014949 A1 AR 014949A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- aralkyl
- cycloalkyl
- heteroaryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 150000002431 hydrogen Chemical group 0.000 abstract 6
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000005330 8 membered heterocyclic group Chemical group 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 235000008206 alpha-amino acids Nutrition 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 230000008619 cell matrix interaction Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000008611 intercellular interaction Effects 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000004436 sodium atom Chemical group 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 150000007979 thiazole derivatives Chemical class 0.000 abstract 1
- 230000005748 tumor development Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de tiazol de la formula I en donde: R1 es grupo III; R2 es formula II; R3 es hidrogeno, alquilo, cicloalquilo, arilo, aralquilo, heteroarilo,carboxilo, alquilo-O-CO- o aralquilo-O-CO-; R4 es hidrogeno, alquilo, cicloalquilo, arilo o heteroarilo; R5 y R6 son cada uno, independientemente, hidrogeno,alquilo, cicloalquilo o heteroarilo; R7 y R8 son cada uno, independientemente, hidrogeno, alquilo, cicloalquilo o aralquilo o R7 y R8 junto con los átomos de Na los que están unidos forman unanillo heterocíclico de 5 a 8 miembros que puede estar sustituido por alquilo; R9 es hidrogeno, alquilo o cicloalquilo; R10 esarilo, aralquilo, heterociclilo, heterociclilalquilo, hidroxilo, hidrogeno o alquilo, o R10 es carboxilo, carboxialquilo, alquilo-O-CO-, aralquilo-O-CO-,alquilo-CO-, aralquilo-CO-, heteroarilalquilo-CO-, alquilsulfonilo, arilsulfonilo o heteroarilsulfonilo y k es 0, o R10 es un alfa.aminoácido enlazado vía elgrupo amino y l es 0 y k es 1; A es carbonilo o sulfonilo; B eshidrogeno, alquilo o cicloalquilo; a y m son 0 o numeros enteros positivos, a es 0 a 2, pero noes 0 cuando R1 es -NH2; b es 0 a 4; c, d, f, g, k, l y m son cada uno, independientemente, 0 o 1, con lo que c, f y g no son simultáneamente 0 y con lo quemno es 0 cuando f o g es 1; i es 0 o 1, con lo que k y l son también 0 cuando i es 0; e es 0 a 3; h es 0 a 5; j es 0 a 2, y la suma de e, h y j es de 2 a 7; asícomo sus sales y ésteres farmacéuticamente utilizables que inhiben la union de proteínasadhesivas a la superficie de diferentes tipos de células y porconsiguiente influencian interacciones célula-célula y célula-matriz; procedimientos para su preparacion, composicion farmacéutica que los contienen,compuestos intermediarios y su uso en forma de preparados farmacéuticos para el control o prevencion de neoplasmas, metástasis tumoral, desarrollo tumoral,osteoporosis, enfermedad de Paget, retinopatía diabética, degeneracion macular, restenosis después de intervencion vascular, psoriasis, artritis, fibrosis,insuficiencia renal, así como infecciones causadas por virus, bacterias u hongos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98100006 | 1998-01-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR014949A1 true AR014949A1 (es) | 2001-04-11 |
Family
ID=8231229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980106723A AR014949A1 (es) | 1998-01-02 | 1998-12-29 | Derivados de tiazol, procedimiento para su preparacion, composicion farmaceutica que los contiene, compuestos intermediarios y su uso para la manufacturade un medicamento |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US6100282A (es) |
| JP (1) | JP3113237B2 (es) |
| KR (1) | KR100312901B1 (es) |
| CN (1) | CN1080720C (es) |
| AR (1) | AR014949A1 (es) |
| AT (1) | ATE233746T1 (es) |
| AU (1) | AU720618B2 (es) |
| BR (1) | BR9900006A (es) |
| CA (1) | CA2257328C (es) |
| CO (1) | CO4990934A1 (es) |
| DE (1) | DE69811844T2 (es) |
| DK (1) | DK0928790T3 (es) |
| ES (1) | ES2193471T3 (es) |
| HK (1) | HK1020953A1 (es) |
| HR (1) | HRP980645A2 (es) |
| HU (1) | HUP9803040A3 (es) |
| ID (1) | ID21936A (es) |
| IL (1) | IL127785A (es) |
| MA (1) | MA26591A1 (es) |
| NO (1) | NO312067B1 (es) |
| NZ (2) | NZ333590A (es) |
| PE (1) | PE20000061A1 (es) |
| PL (1) | PL330619A1 (es) |
| PT (1) | PT928790E (es) |
| RU (1) | RU2218337C2 (es) |
| SG (1) | SG74686A1 (es) |
| TR (1) | TR199802765A3 (es) |
| UY (1) | UY25334A1 (es) |
| YU (1) | YU61398A (es) |
| ZA (1) | ZA9811925B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6919366B2 (en) * | 1998-05-22 | 2005-07-19 | Avanir Pharmaceuticals | Benzimidazole derivatives as modulators of IgE |
| US6911462B2 (en) * | 1998-05-22 | 2005-06-28 | Avanir Pharmaceuticals | Benzimidazole compounds for regulating IgE |
| GB9826174D0 (en) * | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| AU5826100A (en) | 1999-07-13 | 2001-01-30 | F. Hoffmann-La Roche Ag | Benzazepinones and quinazolines |
| US6759425B2 (en) * | 1999-10-21 | 2004-07-06 | Avanir Pharmaceuticals | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| KR100766158B1 (ko) * | 2000-01-19 | 2007-10-10 | 알테온 인크. | 티아졸, 이미다졸 및 옥사졸 화합물, 및 단백질 노화와관련된 장애의 치료 |
| HUP0303460A3 (en) * | 2001-03-12 | 2004-07-28 | Avanir Pharmaceuticals San Die | Benzimidazole compounds for modulating ige and inhibiting cellular proliferation and pharmaceutical compositions containing them |
| MY156407A (en) * | 2002-02-28 | 2016-02-26 | Novartis Ag | 5-phenylthiazole derivatives and use as p13 kinase inhibitors |
| TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| TWI276631B (en) * | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| WO2004024655A2 (en) | 2002-09-12 | 2004-03-25 | Avanir Pharmaceuticals | Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation |
| JP2007501618A (ja) * | 2003-08-08 | 2007-02-01 | アバニール・ファーマシューティカルズ | タンパク質輸送の選択的薬理学的阻害、および関連した、ヒト疾患を治療する方法 |
| US7652146B2 (en) * | 2004-02-06 | 2010-01-26 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors |
| WO2006032322A1 (en) * | 2004-09-20 | 2006-03-30 | 4Sc Ag | NOVEL HETEROCYCLIC NF-κB INHIBITORS |
| WO2008011191A1 (en) * | 2006-07-21 | 2008-01-24 | Replidyne, Inc. | Antibacterial heterocyclic ureas |
| JP5412429B2 (ja) | 2007-07-23 | 2014-02-12 | クレストーン・インコーポレーテッド | 抗細菌性アミド及びスルホンアミド置換複素環式尿素化合物 |
| WO2009015193A1 (en) * | 2007-07-23 | 2009-01-29 | Replidyne, Inc. | Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds |
| TWI504598B (zh) * | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| CN102936257B (zh) * | 2012-08-30 | 2016-03-30 | 齐鲁工业大学 | 一类含银的噻唑西弗碱配合物的结构、制备和用途 |
| EP3645531A1 (en) | 2017-06-29 | 2020-05-06 | Bayer Aktiengesellschaft | Thiazole compounds useful as prmt5 inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2009155B (en) * | 1977-11-07 | 1982-07-21 | Leo Pharm Prod Ltd | Chemical compounds |
| FR2581063B1 (fr) | 1985-04-30 | 1987-07-17 | Chauvin Blache Lab | Amino-2 thiazoles n-substitues, leur procede de preparation et leur application en therapeutique |
| JPS62123180A (ja) * | 1985-11-21 | 1987-06-04 | Otsuka Pharmaceut Factory Inc | ｐ−アミノフエノ−ル誘導体 |
| US5000775A (en) * | 1985-12-31 | 1991-03-19 | Monsanto Company | 2-amino-4,5-disubstituted-oxazole/thiazole compounds as herbicide antidotes |
| JPS6348873A (ja) * | 1986-08-19 | 1988-03-01 | Toshiba Corp | ガスレ−ザ発振装置 |
| US5273982A (en) * | 1990-03-09 | 1993-12-28 | Hoffmann-La Roche Inc. | Acetic acid derivatives |
| CA2037153A1 (en) * | 1990-03-09 | 1991-09-10 | Leo Alig | Acetic acid derivatives |
| FI922867A (fi) * | 1991-06-21 | 1992-12-22 | Tanabe Seiyaku Co | Dikarbonsyraderivat och foerfarande foer framstaellning av dem |
| US5294713A (en) * | 1991-08-23 | 1994-03-15 | Takeda Chemical Industries, Ltd. | 2-piperazinone compounds and their use |
| GB9125970D0 (en) * | 1991-12-06 | 1992-02-05 | Fujisawa Pharmaceutical Co | New compounds |
| US5514643A (en) * | 1993-08-16 | 1996-05-07 | Lucky Ltd. | 2-aminothiazolecarboxamide derivatives, processes for preparing the same and use thereof for controlling phytopathogenic organisms |
| US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| JPH08337579A (ja) * | 1995-06-14 | 1996-12-24 | Fujisawa Pharmaceut Co Ltd | グアニジノチアゾ−ルおよびその抗潰瘍剤、ｈ２−受容体拮抗剤および抗菌剤としての用途 |
| AU679887B2 (en) * | 1995-09-11 | 1997-07-10 | Nihon Nohyaku Co., Ltd. | Azole derivatives, their use, production and usage |
| JPH09295974A (ja) * | 1995-09-11 | 1997-11-18 | Nippon Nohyaku Co Ltd | アゾール誘導体、その用途及びその製造方法並びにその使用方法 |
| CZ207298A3 (cs) * | 1995-12-29 | 1998-11-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fenylthiazolové deriváty, způsob výroby a farmaceutický prostředek |
| MA26487A1 (fr) * | 1997-04-29 | 2004-12-20 | Smithkline Beecham Corp | Heterocyclecetohydrazides inhibiteurs de proteases, procede pour leur preparation et compositions pharmaceutiques les contenant . |
-
1998
- 1998-12-22 US US09/218,567 patent/US6100282A/en not_active Expired - Fee Related
- 1998-12-24 AT AT98124670T patent/ATE233746T1/de not_active IP Right Cessation
- 1998-12-24 NZ NZ333590A patent/NZ333590A/xx unknown
- 1998-12-24 ES ES98124670T patent/ES2193471T3/es not_active Expired - Lifetime
- 1998-12-24 PT PT98124670T patent/PT928790E/pt unknown
- 1998-12-24 DK DK98124670T patent/DK0928790T3/da active
- 1998-12-24 NZ NZ333591A patent/NZ333591A/xx unknown
- 1998-12-24 DE DE69811844T patent/DE69811844T2/de not_active Expired - Fee Related
- 1998-12-28 NO NO19986159A patent/NO312067B1/no unknown
- 1998-12-29 IL IL12778598A patent/IL127785A/en not_active IP Right Cessation
- 1998-12-29 PE PE1998001293A patent/PE20000061A1/es not_active Application Discontinuation
- 1998-12-29 HR HR98100006.0A patent/HRP980645A2/hr not_active Application Discontinuation
- 1998-12-29 AR ARP980106723A patent/AR014949A1/es not_active Application Discontinuation
- 1998-12-29 ZA ZA9811925A patent/ZA9811925B/xx unknown
- 1998-12-30 HU HU9803040A patent/HUP9803040A3/hu unknown
- 1998-12-30 TR TR1998/02765A patent/TR199802765A3/tr unknown
- 1998-12-30 YU YU61398A patent/YU61398A/sh unknown
- 1998-12-30 AU AU96144/98A patent/AU720618B2/en not_active Ceased
- 1998-12-30 SG SG1998005978A patent/SG74686A1/en unknown
- 1998-12-30 PL PL98330619A patent/PL330619A1/xx not_active Application Discontinuation
- 1998-12-30 MA MA25411A patent/MA26591A1/fr unknown
- 1998-12-30 CA CA002257328A patent/CA2257328C/en not_active Expired - Fee Related
- 1998-12-30 CO CO98077476A patent/CO4990934A1/es unknown
- 1998-12-31 CN CN98125982A patent/CN1080720C/zh not_active Expired - Fee Related
- 1998-12-31 KR KR1019980063364A patent/KR100312901B1/ko not_active IP Right Cessation
- 1998-12-31 UY UY25334A patent/UY25334A1/es not_active IP Right Cessation
-
1999
- 1999-01-04 ID IDP990001D patent/ID21936A/id unknown
- 1999-01-04 JP JP11000010A patent/JP3113237B2/ja not_active Expired - Fee Related
- 1999-01-04 BR BR9900006-7A patent/BR9900006A/pt not_active Application Discontinuation
- 1999-01-05 RU RU99100277/04A patent/RU2218337C2/ru not_active IP Right Cessation
- 1999-12-28 HK HK99106136A patent/HK1020953A1/xx not_active IP Right Cessation
-
2000
- 2000-03-15 US US09/526,033 patent/US6320054B1/en not_active Expired - Fee Related
-
2001
- 2001-06-11 US US09/878,704 patent/US6344562B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR014949A1 (es) | Derivados de tiazol, procedimiento para su preparacion, composicion farmaceutica que los contiene, compuestos intermediarios y su uso para la manufacturade un medicamento | |
| AU634751B2 (en) | Substituted pyrimidine derivatives, a process for the preparation thereof, and the use thereof as a tool | |
| BRPI0112986B8 (pt) | compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos | |
| BR9809697A (pt) | Composto, uso, e processo para a preparação do mesmo, composição farmacêutica, e, processo para tratar uma doença de um corpo de animal vivo, incluindo um humano | |
| AR024703A1 (es) | Benzazepinonas y quinazolinas | |
| AR056838A1 (es) | Derivados de 1,2,5-tiadiazol | |
| SE8305299D0 (sv) | Tiaazaforeningar med -laktamer | |
| AR040257A1 (es) | Profarmacos de aminoacidos excitadores | |
| BRPI0507757A (pt) | composto, composição farmacêutica, e agente terapêutico para uma doença na qual a angiogênese ou a hipermeabilidade vascular está envolvida | |
| AR081064A1 (es) | Compuestos de tetraciclina policiclica | |
| MA28039A1 (fr) | Inhibiteurs de metalloproteinases matricielles | |
| AR032607A1 (es) | Composiciones farmaceuticas que contienen sales de hidroxieicosatetraenoato, y el uso de las mismas para la manufactura de un medicamento para el tratamiento de desordenes del ojo seco | |
| AR045999A1 (es) | Compuesto de eter de piperidina, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para prepararlo | |
| ATE25847T1 (de) | Derivate von pyridinium-thiomethylcephalosporinen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate. | |
| AR041481A1 (es) | Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar | |
| SE7701187L (sv) | Nya piperazinderivat och sett att framstella desamma | |
| YU120290A (sh) | Novi derivati r(-)3-kinuklidinola | |
| AR023058A1 (es) | Derivados del tiazol, un procedimiento para su obtencion, composiciones farmaceuticas que los comprenden y el empleo de los mismos para la preparacion demedicamentos | |
| UY25335A1 (es) | Tiazol derivados | |
| ATE273979T1 (de) | Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis | |
| GB1191971A (en) | 2-Amino-6,7-Distributed-4H-1,3-Benzothiazine-4-Ones as Bronchodilators | |
| BRPI0508925A (pt) | derivados de éter, produção e uso deles como agentes farmacêuticos | |
| GB1450452A (en) | Derivatives of pyrazolo 3,4-2,3- pyrido 4,5-e- b-benzo-1,5- diazepinones | |
| AR038730A1 (es) | Derivados de quinolina | |
| ECSP982811A (es) | Derivados de tiazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |